Identifying SLC27A5 as a potential prognostic marker of hepatocellular carcinoma by weighted gene co-expression network analysis and in vitro assays

被引:18
作者
Zhang, Fan [1 ,2 ,3 ]
Xue, Mengjuan [1 ,2 ,3 ]
Jiang, Xin [1 ,2 ,3 ]
Yu, Huiyuan [1 ,2 ,3 ]
Qiu, Yixuan [1 ,2 ,3 ]
Yu, Jiaming [1 ,2 ,3 ]
Yang, Fan [1 ,2 ,3 ]
Bao, Zhijun [1 ,2 ,3 ]
机构
[1] Fudan Univ, Huadong Hosp, Dept Geriatr Med, Shanghai Med Coll, 221 Yanan West Rd, Shanghai 200040, Peoples R China
[2] Fudan Univ, Huadong Hosp, Shanghai Med Coll, Shanghai Key Lab Clin Geriatr Med, 221 Yanan West Rd, Shanghai 200040, Peoples R China
[3] Fudan Univ, Res Ctr Aging & Med, Shanghai 200040, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatocellular carcinoma; WGCNA; SLC27A5; Migration; Epithelial-mesenchymal transition; TRANSPORT PROTEIN 5; CANCER; SORAFENIB; METASTASIS; METABOLISM; PREDICTION; HALLMARKS; PROSTATE; RETINOL; YOUNG;
D O I
10.1186/s12935-021-01871-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundThe incidence and mortality rates of hepatocellular carcinoma are among the highest of all cancers all over the world. However the survival rates are relatively low due to lack of effective treatments. Efforts to elucidate the mechanisms of HCC and to find novel prognostic markers and therapeutic targets are ongoing. Here we tried to identify prognostic genes of HCC through co-expression network analysis.MethodsWe conducted weighted gene co-expression network analysis with a microarray dataset GSE14520 of HCC from Gene Expression Omnibus database and identified a hub module associated with HCC prognosis. Function enrichment analysis of the hub module was performed. Clinical information was analyzed to select candidate hub genes. The expression profiles and survival analysis of the selected genes were performed using additional datasets (GSE45267 and TCGA-LIHC) and the hub gene was identified. GSEA and in vitro experiments were conducted to further verify the function of the hub gene.ResultsGenes in the hub module were mostly involved in the metabolism pathway. Four genes (SLC27A5, SLC10A1, PCK2 and FMO4) from the module were identified as candidate hub genes according to correlation analysis with prognostic indicators. All these genes were significantly down-regulated in tumor tissues compared with non-tumor tissues in additional datasets. After survival analysis and network construction, SLC27A5 was selected as a prognostic marker. GSEA analysis and in vitro assays suggested that SLC27A5 downregulation promoted tumor cell migration via enhancing epithelial-mesenchymal transition.ConclusionSLC27A5 is a potential biomarker of HCC and SLC27A5 downregulation promoted HCC progression by enhancing EMT.
引用
收藏
页数:12
相关论文
共 44 条
[1]   Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].
Abou-Alfa, G. K. ;
Meyer, T. ;
Cheng, A. -L. ;
El-Khoueiry, A. B. ;
Rimassa, L. ;
Ryoo, B. -Y. ;
Cicin, I. ;
Merle, P. ;
Chen, Y. H. ;
Park, J. -W. ;
Blanc, J. -F. ;
Bolondi, L. ;
Klumpen, H. -J. ;
Chan, S. L. ;
Zagonel, V. ;
Pressiani, T. ;
Ryu, M. -H. ;
Venook, A. P. ;
Hessel, C. ;
Borgman-Hagey, A. E. ;
Schwab, G. ;
Kelley, R. K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63
[2]   Context-dependent EMT programs in cancer metastasis [J].
Aiello, Nicole M. ;
Kang, Yibin .
JOURNAL OF EXPERIMENTAL MEDICINE, 2019, 216 (05) :1016-1026
[3]   A Promoter Polymorphism in the Liver-specific Fatty Acid Transport Protein 5 is Associated with Features of the Metabolic Syndrome and Steatosis [J].
Auinger, A. ;
Valenti, L. ;
Pfeuffer, M. ;
Helwig, U. ;
Herrmann, J. ;
Fracanzani, A. L. ;
Dongiovanni, P. ;
Fargion, S. ;
Schrezenmeir, J. ;
Rubin, D. .
HORMONE AND METABOLIC RESEARCH, 2010, 42 (12) :854-859
[4]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[5]   Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Bruix, Jordi ;
Qin, Shukui ;
Merle, Philippe ;
Granito, Alessandro ;
Huang, Yi-Hsiang ;
Bodoky, Gyrogy ;
Pracht, Marc ;
Yokosuka, Osamu ;
Rosmorduc, Olivier ;
Breder, Valeriy ;
Gerolami, Rene ;
Masi, Gianluca ;
Ross, Paul J. ;
Song, Tianqiang ;
Bronowicki, Jean-Pierre ;
Ollivier-Hourmand, Isabelle ;
Kudo, Masatoshi ;
Cheng, Ann-Lii ;
Llovet, Josep M. ;
Finn, Richard S. ;
LeBerre, Marie-Aude ;
Baumhauer, Annette ;
Meinhardt, Gerold ;
Han, Guohong .
LANCET, 2017, 389 (10064) :56-66
[6]   Retinoid pathway and cancer therapeutics [J].
Bushue, Nathan ;
Wan, Yu-Jui Yvonne .
ADVANCED DRUG DELIVERY REVIEWS, 2010, 62 (13) :1285-1298
[7]   Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients [J].
Chen, Chien-Hung ;
Chang, Ting-Tsung ;
Cheng, Ken-Sheng ;
Su, Wei-Wen ;
Yang, Sheng-Shun ;
Lin, Hans Hsienhong ;
Wu, Shun-Sheng ;
Lee, Chuan-Mo ;
Changchien, Chi-Sin ;
Chen, Chien-Jen ;
Sheu, Jin-Chuan ;
Chen, Ding-Shinn ;
Lu, Sheng-Nan .
LIVER INTERNATIONAL, 2006, 26 (07) :766-773
[8]   Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JS']JSMO, KSMO, MOS and SSO [J].
Chen, L-T ;
Martinelli, E. ;
Cheng, A-L ;
Pentheroudakis, G. ;
Qin, S. ;
Bhattacharyya, G. S. ;
Ikeda, M. ;
Lim, H-Y ;
Ho, G. F. ;
Choo, S. P. ;
Ren, Z. ;
Malhotra, H. ;
Ueno, M. ;
Ryoo, B-Y ;
Kiang, T. C. ;
Tai, D. ;
Vogel, A. ;
Cervantes, A. ;
Lu, S-N ;
Yen, C-J ;
Huang, Y-H ;
Chen, S-C ;
Hsu, C. ;
Shen, Y-C ;
Tabernero, J. ;
Yen, Y. ;
Hsu, C-H ;
Yoshino, T. ;
Douillard, J-Y .
ANNALS OF ONCOLOGY, 2020, 31 (03) :334-351
[9]  
Chen X, 2011, Nucleic acids research, V39, P316, DOI [DOI 10.1093/NAR/GKR483, 10.1093/nar/gkr483]
[10]   Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence [J].
Cheng, Hong Sheng ;
Tan, Wei Ren ;
Low, Zun Siong ;
Marvalim, Charlie ;
Lee, Justin Yin Hao ;
Tan, Nguan Soon .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (20)